China National Accord Medicines Corporation Ltd.
First Quarterly Report 2018
April 2018
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord
Medicines Corporation Ltd. (hereinafter referred to as the Company) and its
directors supervisors and senior executives should guarantee the reality
accuracy and completion of the quarterly report there are no any fictitious
statements misleading statements or important omissions carried in this report
and shall take legal responsibilities individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Lin Zhaoxiong person in charge of the Company Wei Pingxiao person in
charge of accounting works and Wang Ying person in charge of accounting
organ (accounting officer) hereby confirm that the Financial Report of this
Quarterly Report is authentic accurate and complete.Section II. Company profile
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data
□ Yes √No
Current Period Same period of last year
Changes of this period over
same period of last year
Operating income (RMB) 10256566731.51 10222459812.55 0.33%
Net profit attributable to shareholders of
the listed company (RMB)
292731685.33 272564318.71 7.40%
Net profit attributable to shareholders of
the listed company after deducting
non-recurring gains and losses (RMB)
284982162.39 271249398.43 5.06%
Net cash flow arising from operating
activities (RMB)
-864716289.96 -502263276.11 -72.16%
Basic earnings per share (RMB/Share) 0.68 0.64 6.25%
Diluted earnings per share (RMB/Share) 0.68 0.64 6.25%
Weighted average ROE 3.07% 3.17% -0.10%
At the end of the reporting
period
At the end of last year
Changes of this period-end
over same period-end of last
year
Total assets (RMB) 23760905981.51 22343643527.77 6.34%
Net assets attributable to shareholder of
listed company (RMB)
9689304031.21 9396572345.88 3.12%
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Item
Amount from year-begin to
period-end
Note
Gains/losses from the disposal of non-current asset (including the
write-off that accrued for impairment of assets)
3830300.39
Revenue from intangible assets
disposal by subsidiary –
Sinopharm Holding Guangxi
Logistic Co. Ltd.Governmental subsidy reckoned into current gains/losses (not
including the subsidy enjoyed in quota or ration according to
national standards which are closely relevant to enterprise’s
business)
2094366.02
Mainly due to the various special
grants received in the current
period.Reversal of impairment reserve for account receivable with
separate impairment testing
3740941.40
The bad debt of receivables
accrual independently previous
year has collected in the period
Other non-operating income and expenditure except for the
aforementioned items
60814.75
Less: impact on income tax 1942073.91
Impact on minority shareholders’ equity (post-tax) 34825.71
Total 7749522.94 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss explain reasons
□ Applicable √ Not applicable
In reporting period the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
Total common shareholders
at the end of report period
17838
Total preference shareholders
with voting rights recovered at
end of reporting period (if
applicable)
0
Top ten shareholders
Shareholder’s
name
Nature of
shareholder
Proportion of
shares held
Amount of shares
held
Amount of
restricted shares
held
Number of share pledged/frozen
State of share Amount
Sinopharm Group
Co. Ltd.
State-owned legal
person
56.06% 239999991 55057700
HTHK/CMG
FSGUFP-CMG
FIRST STATE
CHINA
GROWTH FD
Foreign
Corporation
2.37% 10141182 0
China Life
Insurance Co.Ltd. – tradition –
general insurance
Domestic non
state-owned legal
person
2.05% 8777292 0
products -
005L-CT001
Shen
China United
Property
Insurance
Company
Limited -
Traditional
insurance
products
Domestic non
state-owned legal
person
1.42% 6092905 0
China National
Pharmaceutical
Foreign Trade
Corporation
State-owned legal
person
1.24% 5323043 5323043
GUOTAI
JUNAN
SECURITIES(H
ONGKONG)
LIMITED
Foreign
Corporation
1.23% 5268100 0
TARGET
VALUE FUND
Foreign
Corporation
1.01% 4321860 0
New China Life
Insurance Co.Ltd. – Bonus –
Individual
bonuses -
-018L-FH002
Shen
Domestic non
state-owned legal
person
0.99% 4229772 0
# Beijing
Haoqing Fortune
Investment
Management Co.Ltd. – Haoqing
Value Stable No.8
Investment Fund
Domestic non
state-owned legal
person
0.95% 4048216 0
Central Huijin
Investment Ltd.State-owned legal
person
0.89% 3804400 0
Top ten shareholders with unrestricted shares held
Shareholder’s name Amount of unrestricted shares held
Type of shares
Type Amount
Sinopharm Holding Co. Ltd. 184942291
RMB ordinary
shares
184942291
HTHK/CMG FSGUFP-CMG FIRST
STATE CHINA GROWTH FD
10141182
Domestic listed
foreign shares
10141182
China Life Insurance Co. Ltd. –
tradition –general insurance products
8777292
RMB ordinary
shares
8777292
-005L-CT001 Shen
China United Property Insurance
Company Limited - Traditional
insurance products
6092905
RMB ordinary
shares
6092905
GUOTAI JUNAN
SECURITIES(HONGKONG)
LIMITED
5268100
Domestic listed
foreign shares
5268100
TARGET VALUE FUND 4321860
Domestic listed
foreign shares
4321860
New China Life Insurance Co. Ltd.
– Bonus – Individual bonuses -
-018L-FH002 Shen
4229772
RMB ordinary
shares
4229772
# Beijing Haoqing Fortune
Investment Management Co. Ltd. –
Haoqing Value Stable No.8
Investment Fund
4048216
RMB ordinary
shares
4048216
Central Huijin Investment Ltd. 3804400
RMB ordinary
shares
3804400
UBS AG LONDON BRANCH 3564877
Domestic listed
foreign shares
3564877
Explanation on associated
relationship among the aforesaid
shareholders
Sinopharm Group Co. Ltd. and China National Pharmaceutical Foreign Trade Corporation
have the same actual controller which is China National Pharmaceutical Group Corporation.It is unknown that there exists no associated relationship or belongs to the consistent actionist
among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
Explanation on shareholders
involving margin business about top
ten common stock shareholders (if
applicable)
Beijing Haoqing Fortune Investment Management Co. Ltd. – Haoqing Value Stable No.8
Investment Fund holds shares of the Company through margin trading and negotiable
securities account
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1. Wages payable: a decrease of 70.9527 million Yuan compared with the beginning of the period with a growth rate of -32.90%
mainly because employee’s wages accrual last year are provided in the Period;
2. Asseets impairment loss: a decrease of 1.6439 million Yuan on a year-on-year basis with a growth rate of -600.23% mainly
because the bad debt of receivables accrual independently previous year has collected in the period bad debt provision are switch
back;
3. Income from assets disposal: an increase of 3.7979 million Yuan on a year-on-year basis with a growth rate of 11709.29%
mainly due to the account from property levied by the government in the period;
4. Other income: an increase of 331500 Yuan on a year-on-year basis with a growth rate of 30.46% mainly because government
grant received in the period increased from a year earlier;
5. Non-operation revenue: a decrease of 868300 Yuan on a year-on-year basis with a growth rate of -38.96% mainly because the
payable without payment has written down at same period of last year while no such changes in the period;
6. Non-operation expenditure: a decrease of 1.854 million Yuan on a year-on-year basis with a growth rate of -74.80% mainly due to
the arbitration penalty at same period of last year while no such changes in the period;
7. Refunds of taxes: a decrease of 98200 Yuan on a year-on-year basis with a growth rate of -99.61% mainly because tax refunds
received in the period declined from a year earlier;
8. Net cash flow from operating activities: a decrease of 362 million Yuan on a year-on-year basis with a growth rate of -72.16%
mainly because the cash received from good sale and providing labor service declined from a year earlier;
9. Cash received from investment income: an increase of 332500 Yuan on a year-on-year basis with a growth rate of 78.33% mainly
because the interest for entrusted loans from affiliated enterprise in the period increased from a year earlier;
10. Net cash received from disposal of fixed assets intangible assets and other long-term assets: an increase of 5.556 million Yuan on
a year-on-year basis with a growth rate of 4305.69% mainly because the revenue from intangible assets disposal increased from a
year earlier;
11. Other cash received relating to investment activities: a decrease of 41.8152 million Yuan on a year-on-year basis with a growth
rate of -48.73% mainly because the margin for restructure projects are collected at same period of last year while no such account in
the period;
12. Sub-total of cash inflows from investment activities: a decrease of 35.9267 million Yuan on a year-on-year basis with a growth
rate of -41.60% mainly because the margin for restructure projects are collected at same period of last year while no such account in
the period;
13. Cash paid for the purchase and construction of fixed assets intangible assets and other long-term assets: an increase of 13.2185
million Yuan on a year-on-year basis with a growth rate of 35.18% mainly because expenditure for decoration purchasement
increased from a year earlier for more new stores open in retail section in the period;
14. Cash paid for investment: a decrease of 60 million Yuan on a year-on-year basis with a growth rate of -100% mainly because
medical industry fund are subscribe at same period of last year while no such account in the period;
15. Net cash paid for obtaining subsidiary and other operation units: a decrease of 10 million Yuan on a year-on-year basis with a
growth rate of -100% mainly because subscribed subsidiary’s equity at same period of last year while no such account in the period;
16. Other cash paid relating to investment activities: a decrease of 155 million Yuan on a year-on-year basis with a growth rate of
-77.88% mainly because account for equity restructuring are paid at same period of last year while no such account in the period;
17. Sub-total of cash outflows from investment activities: a decrease of 212 million Yuan on a year-on-year basis with a growth rate
of -69.07% mainly because account for equity restructuring are paid at same period of last year while no such account in the period;
18. Net cash flow from investment activities: an increase of 176 million Yuan on a year-on-year basis with a growth rate of 79.86%
mainly because account for equity restructuring are paid at same period of last year while no such account in the period;
19. Cash received by absorbing investments: an increase of 11.4932 million Yuan on a year-on-year basis mainly because investment
from minority shareholders in the period increased from a year earlier while no such account at same period of last year;
20. Cash received from debts: a decrease of 74.8513 million Yuan on a year-on-year basis with a growth rate of -84.56% mainly
because the loan for current funds received from bank declined from a year earlier;
21. Other cash received relating to financing activities: an increase of 79.0805 million Yuan on a year-on-year basis with a growth
rate of 347.71% mainly because factoring financing in the period increased from a year earlier;
22. Cash paid for distribution of dividend profit or interest payment: an increase of 10.2266 million Yuan on a year-on-year basis
with a growth rate of 49.65% mainly because the payment of buyer notes discount interest and interest of factoring financing are
increased from a year earlier;
23. Other cash paid relating to financing activities: an increase of 774700 Yuan on a year-on-year basis with a growth rate of
32.92% mainly because factoring fee and financing lease interest expenditure increased from a year earlier;
24. Net cash flow from financing activities: an increase of 11.1249 million Yuan on a year-on-year basis with a growth rate of
50.77% mainly because factoring financing increased from a year earlier in the period
II. Analysis and explanation of significant events and their influence and solutions
√Applicable □Not applicable
The proposal on the wholly-owned subsidiary Sinopharm Group Guoda Drugstore Co.Ltd. Bringing in Strategic
Investors by Means of Capital Increase and Share Expansion was deliberated and approved on the 25th meeting of
the 7th session of Board of Directors On Sep. 4th 2017 and the wholly-owned subsidiary Sinopharm Group Guoda
Drugstore Co. Ltd (hereinafter referred to as “Guoda Drugstore”) has got the approval of bringing in one
strategic investor by means of capital increase and share expansion taking assets assessment report as the
reference of pricing. The Company has been listed on stock exchanges at Shanghai United Assets and Equity
Exchange on Sep. 20th 2017 has amassed an interested investor as the actual controller Walgreens Boots
Alliance (NASDAQ: WBA hereinafter referred as “Walgreens” or “WBA”) has subscribed the stock rights of
Guoda Drugstore through taking its wholly-owned subsidiary Walgreens Boots Alliance (Hong Kong) Investments
Limited (hereinafter referred to as “WBAHKIL”) that is based in Hong Kong as the subject of capital increase
with capital increase by 2766.70 million Yuan it holds a 40 percent of stake of Guoda Drugstore. At beginning of
the December in 2017 the Company Sinopharm Group Guoda Drugstore Co.Ltd. and WBAHKIL had signed up
the Registered Capital Increase and Subscription Agreement. On 23 March 2018 the Company received the
“Decision on Non Implementation of Further Review ” (S Anti-Monopoly CSH [2018] No.104) issued by
MOFCOM transferred from Walgreens Boots Alliance Investment Luxemburg Co. Ltd.
By the end of date of disclosure the project needs to acquired approval of foreign investment from MOFCOM. The
Company will continue to fulfill the obligation of information disclosure according to the progress of this project.
Overview of important matters Date of disclosure
Interim report disclosure website query
index
Notice on Progress of the wholly-owned
subsidiary Guoda Drugstore Bringing in
Strategic Investors by Means of Capital
Increase and Share Expansion
2018-03-24
Juchao Website
(http://www.cninfo.com.cn)
III. Commitments completed in Period and those without completed till end of the Period
from actual controller shareholders related parties purchaser and companies
□ Applicable √ Not applicable
The Company has no commitments completed in Period and those without completed till end of the Period from actual controller
shareholders related parties purchaser and companies.IV. Predict of the business performance from January to June 2018
Warnings and reasons of the predict that the cumulative net profit from the begin of the year to the end of next report period may be
loss or have great changes comparing with the same period of last year
□Applicable √Not applicable
V. Securities Investment
□ Applicable √ Not applicable
No security investment in the Period.VI. Derivative investment
□ Applicable √ Not applicable
No derivative investment in the Period.VII. Registration form for receiving research communication and interview in the report
period
□Applicable √Not applicable
The Company had no receiving research communication or interview in the report period.VIII. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the period.IX. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation form controlling shareholders and its related party in the period.Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2018-03-31
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 3262283179.59 4191655438.51
Settlement provisions
Capital lent
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Notes receivable 1276377993.69 1504194764.08
Accounts receivable 9865484747.44 7589412679.88
Accounts paid in advance 417629112.14 516778117.47
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable 57285.56 61441.11
Dividend receivable
Other receivables 633837464.61 657871058.54
Purchase restituted finance asset
Inventories 4130751774.97 3781858238.12
Assets held for sale
Non-current asset due within one
year
Other current assets 81277860.94 78947644.62
Total current assets 19667699418.94 18320779382.33
Non-current assets:
Loans and payments on behalf
Finance asset available for sales 13685760.00 13685760.00
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 1733234745.09 1650619373.09
Investment property 152101534.88 153678339.11
Fixed assets 554170016.26 551710434.02
Construction in progress 27686516.27 22947258.99
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 322922263.94 325751430.88
Expense on Research and
Development
Goodwill 830729152.75 830729152.75
Long-term expenses to be
apportioned
251971852.91 252247050.79
Deferred income tax asset 80898126.88 79472883.06
Other non-current asset 125806593.59 142022462.75
Total non-current asset 4093206562.57 4022864145.44
Total assets 23760905981.51 22343643527.77
Current liabilities:
Short-term loans 1724641669.82 1561354521.64
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 2588298964.51 2732437828.42
Accounts payable 7189784129.58 6144221000.10
Accounts received in advance 167703871.35 216938239.32
Selling financial asset of
repurchase
Commission charge and
commission payable
Wage payable 144703827.72 215656526.54
Taxes payable 199482915.87 223752900.24
Interest payable 6898654.14 7311819.65
Dividend payable 11889443.11 11889443.11
Other accounts payable 1182977735.01 1011128397.26
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Liability held for sale
Non-current liabilities due within 1
year
5531891.01 5434770.70
Other current liabilities 112277.17 112817.65
Total current liabilities 13222025379.29 12130238264.63
Non-current liabilities:
Long-term loans 31600000.00 31600000.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable 8185314.17 9332537.14
Long-term wages payable 1777000.00 1777000.00
Special accounts payable 800000.00 800000.00
Accrual liabilities
Deferred income 123626993.27 125082372.53
Deferred income tax liabilities 70687700.19 71883253.02
Other non-current liabilities 45427343.31 45427343.31
Total non-current liabilities 282104350.94 285902506.00
Total liabilities 13504129730.23 12416140770.63
Owner’s equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital public reserve 3181429064.99 3181429064.99
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus public reserve 214063491.50 214063491.50
Provision of general risk
Retained profit 5865684491.72 5572952806.39
Total owner’s equity attributable to
parent company
9689304031.21 9396572345.88
Minority interests 567472220.07 530930411.26
Total owner’s equity 10256776251.28 9927502757.14
Total liabilities and owner’s equity 23760905981.51 22343643527.77
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 1164288622.01 1776696342.87
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes receivable 9612441.57 64799618.07
Accounts receivable 704186741.40 480467760.92
Account paid in advance 629345.64 1138312.26
Interest receivable 1837134.16 1844294.10
Dividends receivable
Other receivables 1487703176.87 1516037945.71
Inventories 189362652.93 172022676.96
Assets held for sale
Non-current assets maturing within
one year
Other current assets 530332.42 788964.90
Total current assets 3558150447.00 4013795915.79
Non-current assets:
Available-for-sale financial assets
Held-to-maturity investments
Long-term receivables
Long-term equity investments 7266721592.63 7180306084.56
Investment property 2561837.54 2763831.92
Fixed assets 17743826.41 13831103.54
Construction in progress
Project materials
Disposal of fixed assets
Productive biological assets
Oil and natural gas assets
Intangible assets 1129078.57 1287775.78
Research and development costs
Goodwill
Long-term deferred expenses 5219800.75 5543217.86
Deferred income tax assets 2899092.11 2764724.75
Other non-current assets 67141840.00 71808611.00
Total non-current assets 7363417068.01 7278305349.41
Total assets 10921567515.01 11292101265.20
Current liabilities:
Short-term borrowings 641424900.71 707000000.00
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 224521924.73 239563961.30
Accounts payable 472847339.30 434886685.35
Accounts received in advance 1283646.71 1912503.90
Wage payable 23537311.43 33592851.93
Taxes payable 42254243.37 42386907.00
Interest payable 379939.40 669533.78
Dividend payable
Other accounts payable 1000331066.20 1415053655.18
Liability held for sale
Non-current liabilities due within 1
year
Other current liabilities 112277.17 112817.65
Total current liabilities 2406692649.02 2875178916.09
Non-current liabilities:
Long-term loans 31600000.00 31600000.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable
Long-term wages payable
Special accounts payable 800000.00 800000.00
Projected liabilities
Deferred income 2007000.00 2054250.00
Deferred income tax liabilities 3773319.00 3773319.00
Other non-current liabilities
Total non-current liabilities 38180319.00 38227569.00
Total liabilities 2444872968.02 2913406485.09
Owners’ equity:
Share capita 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital public reserve 4407091484.13 4407091484.13
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Retained profit 3427412588.36 3329412821.48
Total owner’s equity 8476694546.99 8378694780.11
Total liabilities and owner’s equity 10921567515.01 11292101265.20
3. Consolidated Profit Statement
In RMB
Item Current Period Last Period
I. Total operating income 10256566731.51 10222459812.55
Including: Operating income 10256566731.51 10222459812.55
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 9962364535.96 9929024160.13
Including: Operating cost 9138308909.43 9158010239.31
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 26770236.12 29737745.69
Sales expenses 606866589.59 548629093.08
Administration expenses 169516240.49 170428020.23
Financial expenses 22272552.43 21945189.25
Losses of devaluation of asset -1369992.10 273872.57
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed
with “-”)
82615372.00 70987332.61
Including: Investment income on
affiliated company and joint venture
82615372.00 70987332.61
Exchange income (Loss is listed
with “-”)
Assets disposal income (Loss is
listed with “-”)
3830300.39 32434.63
Other income 1419763.88 1088241.07
III. Operating profit (Loss is listed with
“-”)
382067631.82 365543660.73
Add: Non-operating income 1360096.85 2228376.43
Less: Non-operating expense 624679.96 2478659.30
IV. Total Profit (Loss is listed with “-”) 382803048.71 365293377.86
Less: Income tax expense 69964333.16 70280239.83
V. Net profit (Net loss is listed with “-”) 312838715.55 295013138.03
(I) Continuous operation net profit
(Net loss is listed with “-”)
312838715.55 295013138.03
(II) Discontinued operation net
profit (Net loss is listed with “-”)
Net profit attributable to owner’s of
parent company
292731685.33 272564318.71
Minority shareholders’ gains and
losses
20107030.22 22448819.32
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method which
will not be reclassified subsequently to
profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method which
will be reclassified subsequently to profit
or loss
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale financial
assets
4. The effect hedging portion
of gains or losses arising from cash flow
hedging instruments
5. Translation differences
arising on translation of foreign currency
financial statements
6. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 312838715.55 295013138.03
Total comprehensive income
attributable to owners of parent Company
292731685.33 272564318.71
Total comprehensive income
attributable to minority shareholders
20107030.22 22448819.32
VIII. Earnings per share:
(i) Basic earnings per share 0.68 0.64
(ii) Diluted earnings per share 0.68 0.64
Enterprise combine under the same control in the Period the combined party realized net profit of 0 Yuan before combination and
realized -1096.00 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
4. Profit Statement of Parent Company
In RMB
Item Current Period Last Period
I. Operating income 838120017.53 802057016.78
Less: Operating cost 799779364.60 769324785.10
Operating tax and extras 835459.34 1519528.19
Sales expenses 12616898.48 12395531.55
Administration expenses 17050142.14 13154355.35
Financial expenses -8050984.45 -18888226.18
Losses of devaluation of asset 615777.60 -110682.96
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is
listed with “-”)
86415508.07 76265472.96
Including: Investment income
on affiliated company and joint venture
86415508.07 76265472.96
Assets disposal income (Loss is
listed with “-”)
1087.38
Other income 326108.76 641300.00
II. Operating profit (Loss is listed with
“-”)
102014976.65 101569586.07
Add: Non-operating income 1.36 6429.22
Less: Non-operating expense 127688.63 1011760.15
III. Total Profit (Loss is listed with “-”) 101887289.38 100564255.14
Less: Income tax expense 3887522.50 6181603.71
IV. Net profit (Net loss is listed with
“-”)
97999766.88 94382651.43
(I) Continuous operation net profit
(Net loss is listed with “-”)
97999766.88 94382651.43
(II) Discontinued operation net
profit (Net loss is listed with “-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale
financial assets
4. The effect hedging
portion of gains or losses arising from
cash flow hedging instruments
5. Translation differences
arising on translation of foreign
currency financial statements
6. Other
VI. Total comprehensive income 97999766.88 94382651.43
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Cash Flow Statement
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor
services
9559665373.83 10328284481.94
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
investment
Net increase of amount from
disposal financial assets that measured
by fair value and with variation
reckoned into current gains/losses
Cash received from interest
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 389.03 98628.11
Other cash received concerning
operating activities
148125927.35 207536266.55
Subtotal of cash inflow arising from
operating activities
9707791690.21 10535919376.60
Cash paid for purchasing
commodities and receiving labor
service
9484567939.67 9820844639.93
Net increase of customer loans
and advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 506267191.33 479482361.89
Taxes paid 263785194.50 295430548.56
Other cash paid concerning
operating activities
317887654.67 442425102.33
Subtotal of cash outflow arising from
operating activities
10572507980.17 11038182652.71
Net cash flows arising from operating
activities
-864716289.96 -502263276.11
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
income
757007.78 424502.22
Net cash received from disposal of
fixed intangible and other long-term
assets
5685052.04 129038.95
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
44000000.00 85815179.38
Subtotal of cash inflow from investing
activities
50442059.82 86368720.55
Cash paid for purchasing fixed
intangible and other long-term assets
50791078.84 37572554.85
Cash paid for investment 60000000.00
Net increase of mortgaged loans
Net cash received from
subsidiaries and other units obtained
10000000.00
Other cash paid concerning
investing activities
43999800.00 198944422.63
Subtotal of cash outflow from investing
activities
94790878.84 306516977.48
Net cash flows arising from investing
activities
-44348819.02 -220148256.93
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
11493200.00
Including: Cash received from
absorbing minority shareholders’
11493200.00
investment by subsidiaries
Cash received from loans 13671657.79 88522962.94
Cash received from issuing bonds
Other cash received concerning
financing activities
101823564.80 22743050.43
Subtotal of cash inflow from financing
activities
126988422.59 111266013.37
Cash paid for settling debts 60000000.00 66403745.30
Cash paid for dividend and profit
distributing or interest paying
30822293.85 20595737.67
Including: Dividend and profit of
minority shareholder paid by
subsidiaries
2581864.12 508903.35
Other cash paid concerning
financing activities
3127895.57 2353233.82
Subtotal of cash outflow from
financing activities
93950189.42 89352716.79
Net cash flows arising from financing
activities
33038233.17 21913296.58
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
equivalents
-876026875.81 -700498236.46
Add: Balance of cash and cash
equivalents at the period -begin
3673498691.48 3150915425.49
VI. Balance of cash and cash
equivalents at the period -end
2797471815.67 2450417189.03
6. Cash Flow Statement of Parent Company
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor
services
762534474.46 742518400.20
Write-back of tax received
Other cash received concerning
operating activities
35545170.43 7196336.45
Subtotal of cash inflow arising from
operating activities
798079644.89 749714736.65
Cash paid for purchasing
commodities and receiving labor
service
809539295.55 802517675.95
Cash paid to/for staff and workers 28353128.47 25437740.17
Taxes paid 9359247.21 31457445.98
Other cash paid concerning
operating activities
5064967.04 5269455.38
Subtotal of cash outflow arising from
operating activities
852316638.27 864682317.48
Net cash flows arising from operating
activities
-54236993.38 -114967580.83
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
income
15164809.14 18996884.57
Net cash received from disposal of
fixed intangible and other long-term
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
567200000.00 628959200.00
Subtotal of cash inflow from investing
activities
582364809.14 647956084.57
Cash paid for purchasing fixed
intangible and other long-term assets
3475188.15 2112339.07
Cash paid for investment 60000000.00
Net cash received from
subsidiaries and other units
10000000.00
Other cash paid concerning
investing activities
564900000.00 962127450.00
Subtotal of cash outflow from investing 568375188.15 1034239789.07
activities
Net cash flows arising from investing
activities
13989620.99 -386283704.50
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from loans 10000000.00 10000000.00
Cash received from issuing bonds
Other cash received concerning
financing activities
3631131894.36 2494200152.44
Subtotal of cash inflow from financing
activities
3641131894.36 2504200152.44
Cash paid for settling debts 10000000.00 10000000.00
Cash paid for dividend and profit
distributing or interest paying
9054055.96 1542929.92
Other cash paid concerning
financing activities
4194238186.87 2571601495.22
Subtotal of cash outflow from
financing activities
4213292242.83 2583144425.14
Net cash flows arising from financing
activities
-572160348.47 -78944272.70
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
equivalents
-612407720.86 -580195558.03
Add: Balance of cash and cash
equivalents at the period -begin
1776696342.87 1342041409.86
VI. Balance of cash and cash
equivalents at the period -end
1164288622.01 761845851.83
II. Audit report
Whether the first quarterly report had been audited or not
□ Yes √ No
The first quarterly report of the Company had not been audited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
24 April 2018
沪公网安备31011802005267号
